or Try an Advanced Search...

    Technical Analysis for ATHA - Athira Pharma, Inc.

    Grade Last Price % Change Price Change
    D 0.64 -1.00% -0.01
    ATHA closed down 1.0 percent on Wednesday, November 20, 2024, on 4 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Down
    Historical ATHA trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Wide Bands Range Expansion -1.00%
    Wide Bands Range Expansion 0.11%
    Down 3 Days in a Row Weakness 0.11%
    Down 4 Days in a Row Weakness 0.11%
    1,2,3 Pullback Bullish Bullish Swing Setup -4.15%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.15%
    NR7 Range Contraction -4.15%
    Older End-of-Day Signals for ATHA ...

       Recent Intraday Alerts

    Alert Time
    Fell Below Previous Day's Low about 22 hours ago
    Down 2 % about 22 hours ago
    Down 1% about 22 hours ago
    Up 1% about 22 hours ago
    60 Minute Opening Range Breakout 2 days ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ATHA Chart by TradingView
    Basic chart:

    Profile

    Athira, headquartered in Seattle, is a drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders. Athira is currently advancing its lead therapeutic candidate, NDX-1017, a novel small molecule therapeutic, in later-stage clinical trials for Alzheimer’s.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Drug Development Nasdaq 100 Index Innovative Therapies Brain Disorders

    Is ATHA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 7 Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
    Nov 4 US Penny Stocks: November 2024's Top Picks To Consider
    Nov 1 Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
    Sep 17 Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
    Sep 5 Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
    Sep 4 Athira plunges as Alzheimer’s trial setback leads to downgrades
    Sep 4 Alzheimer’s Trial Failure Sends Athira Stock Down 75%
    Sep 4 Athira’s stock topples after Alzheimer’s drug flops in Phase II/III trial
    Sep 4 ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
    Sep 4 Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
    See more ATHA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.2984
    52 Week Low 0.4115
    Average Volume 6,017,260
    200-Day Moving Average 2.18
    50-Day Moving Average 0.52
    20-Day Moving Average 0.62
    10-Day Moving Average 0.69
    Average True Range 0.08
    RSI (14) 49.75
    ADX 33.61
    +DI 27.60
    -DI 18.34
    Chandelier Exit (Long, 3 ATRs) 0.57
    Chandelier Exit (Short, 3 ATRs) 0.67
    Upper Bollinger Bands 0.84
    Lower Bollinger Band 0.40
    Percent B (%b) 0.55
    BandWidth 71.84
    MACD Line 0.01
    MACD Signal Line 0.01
    MACD Histogram 0.0092
    Fundamentals Value
    Market Cap 24.44 Million
    Num Shares 38.1 Million
    EPS -3.17
    Price-to-Earnings (P/E) Ratio -0.20
    Price-to-Sales 0.00
    Price-to-Book 0.82
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.68
    Resistance 3 (R3) 0.69 0.67 0.68
    Resistance 2 (R2) 0.67 0.66 0.67 0.67
    Resistance 1 (R1) 0.66 0.66 0.67 0.66 0.67
    Pivot Point 0.64 0.64 0.65 0.64 0.64
    Support 1 (S1) 0.63 0.63 0.64 0.63 0.61
    Support 2 (S2) 0.62 0.63 0.62 0.61
    Support 3 (S3) 0.60 0.62 0.61
    Support 4 (S4) 0.60